Paul Tudor Jones's NPCE Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 135,705 shares of NeuroPace, Inc. (NPCE) worth $1.78 M, representing 0.00% of the portfolio. First purchased in 2025-Q1, this short-term holding has been held for 5 quarters.
Based on 13F filings, Paul Tudor Jones has maintained this position in NPCE for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 70,881 shares. Largest reduction occurred in Q1 2026, reducing 57,641 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's NeuroPace (NPCE) Holding Value Over Time
Track share changes against reported price movement
Quarterly NeuroPace (NPCE) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -57,641 | Reduce 29.81% | 135,705 | $13.15 |
| Q4 2025 | +39,648 | Add 25.80% | 193,346 | $15.44 |
| Q3 2025 | +34,807 | Add 29.28% | 153,698 | $10.31 |
| Q2 2025 | +70,881 | Add 147.64% | 118,891 | $11.14 |
| Q1 2025 | +48,010 | New Buy | 48,010 | $12.29 |
Paul Tudor Jones's NeuroPace Investment FAQs
Paul Tudor Jones first purchased NeuroPace, Inc. (NPCE) in Q1 2025, acquiring 48,010 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held NeuroPace, Inc. (NPCE) for 5 quarters since Q1 2025.
Paul Tudor Jones's largest addition to NeuroPace, Inc. (NPCE) was in Q2 2025, adding 118,891 shares worth $1.32 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 135,705 shares of NeuroPace, Inc. (NPCE), valued at approximately $1.78 M.
As of the Q1 2026 filing, NeuroPace, Inc. (NPCE) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in NeuroPace, Inc. (NPCE) was 193,346 shares, as reported at the end of Q4 2025.